Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $319.06 in the prior trading day, BeOne Medicines Ltd ADR (NASDAQ: ONC) closed at $310.67, down -2.63%. In other words, the price has decreased by -$2.63 from its previous closing price. On the day, 0.76 million shares were traded. ONC stock price reached its highest trading level at $315.54 during the session, while it also had its lowest trading level at $301.01.
Ratios:
Our goal is to gain a better understanding of ONC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 57.93. For the most recent quarter (mrq), Quick Ratio is recorded 2.17 and its Current Ratio is at 2.39. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.25.
On September 18, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $385.
On April 07, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $312.RBC Capital Mkts initiated its Outperform rating on April 07, 2025, with a $312 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when JOHN V OYLER bought 100,000 shares for $319.06 per share.
Lee Chan Henry sold 332 shares of ONC for $107,900 on Dec 11 ’25. The SVP, General Counsel now owns 0 shares after completing the transaction at $325.00 per share. On Dec 10 ’25, another insider, Lee Chan Henry, who serves as the SVP, General Counsel of the company, sold 332 shares for $318.28 each. As a result, the insider received 105,669 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ONC now has a Market Capitalization of 34378104832 and an Enterprise Value of 443898462208. As of this moment, BeOne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 597.67, and their Forward P/E ratio for the next fiscal year is 46.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.35 while its Price-to-Book (P/B) ratio in mrq is 8.32. Its current Enterprise Value per Revenue stands at 89.267 whereas that against EBITDA is 1352.644.
Stock Price History:
The Beta on a monthly basis for ONC is 0.47, which has changed by 0.7818608 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, ONC has reached a high of $385.22, while it has fallen to a 52-week low of $170.99. The 50-Day Moving Average of the stock is -5.98%, while the 200-Day Moving Average is calculated to be 7.93%.
Shares Statistics:
The stock has traded on average 256.56K shares per day over the past 3-months and 247160 shares per day over the last 10 days, according to various share statistics. A total of 101.77M shares are outstanding, with a floating share count of 101.28M. Insiders hold about 0.46% of the company’s shares, while institutions hold 32.24% stake in the company. Shares short for ONC as of 1764288000 were 1523163 with a Short Ratio of 5.94, compared to 1761868800 on 1566239. Therefore, it implies a Short% of Shares Outstanding of 1523163 and a Short% of Float of 1.96.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.51, with high estimates of $1.03 and low estimates of $0.25.
Analysts are recommending an EPS of between $4.29 and $2.45 for the fiscal current year, implying an average EPS of $3.4. EPS for the following year is $6.44, with 16.0 analysts recommending between $9.41 and $1.03.
Revenue Estimates
12 analysts predict $1.45B in revenue for. The current quarter. It ranges from a high estimate of $1.52B to a low estimate of $1.33B. As of. The current estimate, BeOne Medicines Ltd ADR’s year-ago sales were $1.13BFor the next quarter, 12 analysts are estimating revenue of $1.38B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.3B.
A total of 32 analysts have provided revenue estimates for ONC’s current fiscal year. The highest revenue estimate was $5.44B, while the lowest revenue estimate was $5.12B, resulting in an average revenue estimate of $5.28B. In the same quarter a year ago, actual revenue was $3.81BBased on 34 analysts’ estimates, the company’s revenue will be $6.41B in the next fiscal year. The high estimate is $7B and the low estimate is $5.72B.
